BioCatalystWatch
AVIRWorkspace / AVIR / OverviewCompany library
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. (AVIR)

Website

Price
Market cap
Next catalystEarly Q1 2027bemnifosbuvir and ruzasvir — C-BEYOND / C-FORWARD · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

AT-587

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AT-587

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

ruzasvir (RZR)

HCV NS5A

PreINDP1P2P3FilingApproved
bemnifosbuvir (AT-527)

Viral RNA polymerase (RdRp) × HCV NS5B polymerase × SARS-CoV-2 nsp12 RdRp/NiRAN

PreINDP1P2P3FilingApproved
AT-2490

PreINDP1P2P3FilingApproved

History / paused

bemnifosbuvir (AT-527)

Viral RNA polymerase (RdRp) × HCV NS5B polymerase × SARS-CoV-2 nsp12 RdRp/NiRAN

PreINDP1P2P3FilingApproved
bemnifosbuvir and ruzasvir

HCV NS5B polymerase × HCV NS5A

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AVIR PR & News

PR & News

AVIR SEC archive